Skip to main content

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)

Hong Kong Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
54.5Fair

ValueMarkers Composite Index

Top 50%#22,246 of 44,714
Undervalued

75% below intrinsic value ($10)

UndervaluedFair ValueOvervalued
Piotroski
3/9
Weak
Beneish
-2.28
Low Risk
Altman
2.31
Grey Zone
DCF Value
$10
Undervalued
ROIC
4.4%
Low
P/E
12.5
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) — VMCI valuation read

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited sits at VMCI 55/100, with the Healthcare sector median at 50. That 5-point spread is the first thing to note on 0874.HK: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 0874.HK are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 0874.HK: 0874.HK trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 1.1x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

0874.HK fell 3.7% over the trailing 7 days, with a -6.2% read on a 30-day basis.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

CEO: Hong Li28,138 employeesCNwww.gybys.com.cn

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0874.HK’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.